Zenith® TXD Post-market Surveillance in Japan | NCT02663739 | Trialant

Zenith® TXD Post-market Surveillance in Japan | NCT02663739 | Trialant

Arms/Interventions Module

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Zenith® TXD	Device	Zenith® TXD Dissection Stent Graft System for treatment of patients with aortic dissection of the descending thoracic aorta	Aortic Dissection

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Rate of major adverse events	Major adverse events will include death, aortic rupture, conversion to open surgical repair, spinal cord ischemia, retrograde progression of dissection, myocardial infarction, renal failure requiring dialysis, intestinal ischemia, stroke, paraplegia, and > 72 hours artificial respiratory assistance.	5 years

Contacts/Locations Module

Overall Officials

Name	Affiliation	Role
Masaaki Kato, MD	Morinomiya Hospital	Study Chair
Kimihiko Kichikawa, MD	Nara Medical University Hospital	Study Chair
Hideyuki Shimizu, MD	Keio University Hospital	Study Chair
Joseph Lombardi, MD	The Cooper Health System	Study Chair

Condition Browse Module